Personalized medicine approach for novel microglia-associated genetic variants in Alzheimer's disease
Acronym
PMG-AD
Description of the granted funding
Alzheimer's disease (AD), the main cause of dementia world-wide, is clinically manifested as memory impairment and executive dysfunction. Most of the pathomechanistic studies in AD have so far largely concentrated on neurons, neglecting the role of other brain cells in neurodegeneration. The goal in the PMG-AD is to establish a personalized medicine-based approach for identification of early biomarkers and therapeutic targets in AD by focusing on novel AD-associated genetic variants in ABI3 and PLCG2 genes and consequently utilizing the latest research methodologies, human-based model systems and cohorts, and PET imaging, multilevel omics, integrative bioinformatic and endophenotype analyses to advance understanding of the role of microglia in AD. This new knowledge will advance the identification of novel candidates as personalized medicine-based biomarker and therapeutic targets for AD.
Show moreStarting year
2020
End year
2023
Granted funding
Role in consortium of the Academy of Finland
Leader
Other consortium parties
Funder
Research Council of Finland
Funding instrument
Kansainvälinen yhteisrahoitteinen ohjelma
Other information
Funding decision number
334802
Fields of science
Neurosciences
Research fields
Neurotiede
Identified topics
brain, neuroscience